Prof Johann de Bono, who led the trials of Zytiga (Abiraterone) at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, said: "I'm thrilled that this drug will now be routinely available for eligible patients on the NHS.
"Abiraterone acetate is one of only a handful of life-extending drugs for these patients and, importantly, it can also improve the quality of life.
"Some of my patients have been taking abiraterone for several years through clinical trials and are still pain free."
No comments:
Post a Comment